## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.0% below STRENGTH zone (3.0-6.0%); PEG 1.04 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($324.84)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Wall Street Sees an 18% Upside to Elevance Health (ELV)**
- Source: Insider Monkey | 20251217T132021 | Bullish | Relevance: 100%
- Elevance Health (ELV) is seen by Wall Street as having an 18% upside, with analysts like TD Cowen reiterating a Buy recommendation and raising the price target to $400. CEO Seth Klarman holds a substantial stake in the company. Despite some challenges, Elevance Health's Q3 2025 results showed strong operating revenue and adjusted diluted EPS growth.

**2. UnitedHealth, Elevance, Aetna tops in insurance market share: AMA**
- Source: Modern Healthcare | 20251217T110821 | Bullish | Relevance: 100%
- According to the American Medical Association, UnitedHealth Group, Elevance Health, and Blue Cross Blue Shield of Michigan are among the top ten in health insurance market share for 2024. The article highlights the dominant positions of these major insurers.

**3. Elevance Health (NYSE:ELV) Price Target Lowered to $352.00 at Morgan Stanley**
- Source: MarketBeat | 20251217T145119 | Somewhat-Bearish | Relevance: 100%
- Morgan Stanley has lowered its price target for Elevance Health (NYSE:ELV) to $352.00 from $359.00, maintaining an "equal weight" rating, which suggests a modest 1.78% potential upside. Despite this, the company reported strong Q3 earnings, exceeding consensus estimates with EPS of $6.03 and revenues of $50.09 billion. Other analysts have a mixed view, with a consensus "Moderate Buy" rating and an average price target of $400.44.

**4. Morgan Stanley Adjusts Price Target on Elevance Health to $352 From $359, Maintains Equalweight Rating**
- Source: marketscreener.com | 20251217T144119 | Neutral | Relevance: 100%
- Morgan Stanley has revised its price target for Elevance Health (NYSE: ELV) down to $352 from $359, while maintaining an "Equalweight" rating on the stock. This adjustment comes amidst other analyst actions, with Baird recently increasing its price target to $340 and TD Cowen maintaining a "Buy" rating with a $400 target. Elevance Health, a leading American health insurance group, provides a wide range of medical and specialty products, serving nearly 45.7 million medical members at the end of 2024.

**5. Texas Permanent School Fund Corp Trims Stock Holdings in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251217T105606 | Neutral | Relevance: 100%
- Texas Permanent School Fund Corp recently reduced its stake in Elevance Health, Inc. ($ELV) by 36.7%, selling 9,209 shares and retaining 15,857 shares valued at $6.17 million. Despite this trimming, other institutional investors have mostly increased their holdings in the company. Elevance Health, which operates as a health benefits company, reported strong third-quarter earnings, beating analyst estimates, and announced a quarterly dividend of $1.71 per share.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Morgan Stanley | $352 | $359 | -2% |
| 2025-11-26 | TD Cowen | $400 | $380 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Morgan Stanley | main | Equal-Weight |
| 2025-11-26 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.04 suggests fair value with growth premium. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $77.6B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.04 |
| Forward P/E | 12.8 |
| Current P/E | 11.5 |
| YoY Growth | -10.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 7.9% to 1.0% (-6.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.0pp (needs >3.0% for momentum thesis). MRS_5 (-2.2%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.97x), long-term trend not supportive. MACD histogram positive (1.36), confirming momentum. RSI neutral at 55. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.00% (CS: 50) | Neutral |
| RSI_14 | 54.9 | Neutral |
| MACD Histogram | 1.36 | Bullish |
| vs SMA20 | 1.020x | Above |
| vs SMA50 | 1.028x | Above |
| vs SMA200 | 0.966x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $344.62
- **Stop Loss:** $324.84 (5.7% risk)
- **Target:** $364.40 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 48
- **Position Value:** $16,541.76
- **Portfolio %:** 16.54%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*